5 days Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $95.00 at Morgan StanleyMarketBeat
Morgan Stanley boosted their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday.
Morgan Stanley (MS) · Nasdaq 100 · Science
X